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Abstract
This article is part of a series of papers examining ethical issues in cluster randomized trials (CRTs) in health
research. In the introductory paper in this series, we set out six areas of inquiry that must be addressed if the CRT
is to be set on a firm ethical foundation. This paper addresses the first of the questions posed, namely, who is the
research subject in a CRT in health research? The identification of human research subjects is logically prior to the
application of protections as set out in research ethics and regulation. Aspects of CRT design, including the fact
that in a single study the units of randomization, experimentation, and observation may differ, complicate the
identification of human research subjects. But the proper identification of human research subjects is important if
they are to be protected from harm and exploitation, and if research ethics committees are to review CRTs
efficiently.
We examine the research ethics literature and international regulations to identify the core features of human
research subjects, and then unify these features under a single, comprehensive definition of human research
subject. We define a human research subject as any person whose interests may be compromised as a result of
interventions in a research study. Individuals are only human research subjects in CRTs if: (1) they are directly
intervened upon by investigators; (2) they interact with investigators; (3) they are deliberately intervened upon via
a manipulation of their environment that may compromise their interests; or (4) their identifiable private
information is used to generate data. Individuals who are indirectly affected by CRT study interventions, including
patients of healthcare providers participating in knowledge translation CRTs, are not human research subjects
unless at least one of these conditions is met.
Introduction
This article is part of a series of papers examining ethi-
cal issues in cluster randomized trials (CRTs) in health
research. CRTs are used increasingly in knowledge
translation research, quality improvement research,
community based intervention studies, public health
research, and research in developing countries. While a
small and growing literature explores ethical aspects of
CRTs, cluster trials raise difficult issues that have not
been adequately addressed. In the introductory paper in
this series, we set out six areas of inquiry that must be
addressed if the cluster trial is to be set on a firm ethical
foundation [1]. These include identifying human
research subjects, obtaining informed consent, the
applicability of clinical equipoise, benefit-harm analysis,
the protection of vulnerable populations, and the role
and authority of gatekeepers in CRTs. This paper
addresses the first of the questions posed, namely, who
is the research subject in a CRT in health research?
CRTs are used in a range of fields, including educa-
tion, criminology, public health, and health services
research [2]. The identification of human research sub-
jects must logically occur prior to the application of
protections as set out in research ethics and regulation.
Yet, the identification of human research subjects in a
CRT may be unclear. Aspects of CRT design, including
the fact that in a single study the units of randomiza-
tion, experimentation, and observation may differ,
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complicate the identification of human research sub-
jects. Are individual cluster members always human
research subjects? In some CRTs, health professionals
are randomly assigned to receive an experimental inter-
vention, and their patients are the source of outcome
data. Are the health care professionals human research
subjects? Are patients human research subjects if the
intervention administered to the healthcare professional
indirectly affects their care?
The proper identification of human research subjects
in a CRT is important for two reasons. First, misidenti-
fying human research subjects in CRTs can have impor-
tant consequences. If we fail to identify human research
subjects in a CRT, then we may not be able to protect
their interests adequately. If we are overly inclusive in
identifying human research subjects, investigators will
be subjected to regulatory burdens that may hamper
important research. Second, as a pragmatic concern for
research ethics committees, human research subjects
must be correctly identified before ethical and regulatory
requirements of informed consent, harm-benefit analy-
sis, and fair subject selection can be applied. If research
ethics committees are to review CRTs efficiently, human
research subjects must be identified accurately.
This paper proposes a definition of human research
subject that investigators and research ethics committees
can apply to all CRTs in health research. We contend
that the answer to the question “who is the research
subject in a CRT in health research?” may vary, depend-
ing on the study design, population, or intervention
under investigation. The definition proposed in this
paper will help ensure that subjects in CRTs are identi-
fied appropriately and protected without needlessly
hampering important research.
Examples: Challenges in identifying the human
research subject in CRTs
CRTs are heterogeneous with respect to design, popula-
tion, and intervention. The following four examples
illustrate the complexity of identifying human research
subjects in CRTs and highlight the need for a definition
of human research subject that can be employed across
the spectrum of CRTs in health research.
Example 1: The COMMIT trial
The Community Intervention Trial for Smoking Cessa-
tion (COMMIT) was designed to test the effectiveness
of a comprehensive, community-oriented approach to
influence citizens’ smoking behaviours [3,4]. Twenty-two
(22) communities with populations between 50,000 and
250,000 in the USA and Canada were paired on geo-
graphic location, size, and socio-demographic factors
and one community in each pair was randomly assigned
to the intervention. The intervention, which was
delivered over a 4-year period, required active involve-
ment of the communities and included activities focused
on public education using mass media and organized
community events, training of health care providers in
cessation techniques, promotion of smoke-free policies
in health care facilities and worksites, promotion of poli-
cies to restrict the sale of tobacco to youth, and devel-
opment of smoking cessation resources and activities in
each community. Population-based surveys, using ran-
dom digit telephone dialing, were used to measure out-
comes in the study. Prior to randomization of
communities, and again at the end of the intervention,
cross-sectional samples of approximately 2500 house-
holds per community were surveyed about their smok-
ing behaviours. In addition, cohorts of approximately
550 heavy and 550 light-to-moderate smokers, who
were willing to be contacted annually about their smok-
ing status, were identified in each community. Main
outcome measures were quit rates in the cohorts of
smokers, as well as cross-sectional changes in the preva-
lence of smoking from pre- to post-intervention.
Although the intervention significantly improved quit
rates among light-to-moderate smokers, there was no
significant impact on quit rates among heavy smokers
or on the community prevalence of smoking.
Who were the human research subjects in this study?
All residents in intervention and control communities?
Only those residents participating in the telephone sur-
veys? The cohorts of smokers followed prospectively
over time?
Example 2: A CRT of bed net distribution to reduce
malaria prevalence
Sochantha and colleagues [5] report on a CRT designed
to evaluate the impact of widespread distribution of
insecticide-treated bed nets on malaria morbidity and
mortality in remote areas of Cambodia. Thirty-six (36)
villages, not previously included in the national malaria
control program, were paired on their baseline preva-
lence of malaria and one village in each pair was ran-
domly assigned to the intervention. Villages in the
control arm received bed nets at the end of the study.
Volunteers were identified in control and intervention
villages and trained to recognize malaria symptoms,
conduct diagnostic tests, and administer treatment. The
volunteers conducted passive surveillance by recording
information about the age and sex of the patient, the
test results and treatments given. Ethical approval was
obtained from Cambodia’s Ministry of Health. The main
outcomes were proxy measures of malaria incidence and
the prevalence of malaria after the intervention. Malaria
incidence was estimated using the number of positive
consultations with malaria workers, with local popula-
tion size obtained from census lists maintained by
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village heads. Malaria prevalence was estimated using
blood samples collected from cross-sectional samples of
approximately 250 randomly selected residents per vil-
lage before and after the intervention. The intervention
did not have a significant impact on malaria prevalence,
but a non-significant trend towards decreased malaria
incidence was observed.
Who were the human research subjects in this study?
All residents in intervention and control villages? Those
who received bed nets? Those who provided blood
samples?
Example 3: A CRT comparing interventions to improve
primary care prescribing
Naughton and colleagues [6] report on a CRT designed to
compare the effectiveness of two quality improvement
interventions to increase prescribing of antiplatelet and
lipid lowering medications for patients with cardiovascular
disease or diabetes mellitus. A total of 110 General Practi-
tioners (GPs) from 98 family practices in Ireland agreed to
participate. Practices were randomly assigned to the inter-
vention or control arm of the study. GPs in the interven-
tion arm received a postal bulletin containing a
personalized summary of their prescribing practices plus
an educational outreach visit, while GPs in the control
arm received a postal bulletin alone. Prescription data
used to prepare the personalized summaries were obtained
from the national pharmacy claims insurance database,
which contains unique patient and GP identification num-
bers, as well as demographic information about the
patients. The personalized summaries contained aggregate
information about prescription rates and no information
that could be used to identify individual patients. Ethical
approval was obtained from the Irish College of General
Practitioners. The main outcome measure was the change
in the proportion of patients with cardiovascular disease
or diabetes receiving appropriate drug therapies from pre-
to post-intervention. All GPs received a postal survey
questionnaire, which included questions about the per-
ceived effects of the intervention on their practice. There
were small increases in prescribing of preventive therapies
in both arms of the study, but no significant differences
between the arms.
In this study, there were no direct interventions on
patients, nor use of identifiable private information. Who
were the human research subjects in this study? All
patients in participating practices? All of the cardiovascu-
lar disease and diabetes mellitus patients in participating
practices? The physicians receiving the interventions [7,8]?
Example 4: A CRT comparing modes of educating
patients prior to breast cancer surgery
Goel and colleagues [9] report on a CRT designed to
evaluate a decision aid to inform early breast cancer
patients about their treatment options. General surgeons
practicing in community hospitals in Ontario were
invited to participate in the study. Interested surgeons
were randomly assigned to either the intervention or
control arm. Surgeons in both arms were asked to iden-
tify and enroll eligible patients presenting for breast
biopsies. Surgeons in the intervention arm were directed
to administer the decision aid (which consisted of an
audiotape and a workbook), while surgeons in the con-
trol arm were directed to administer a simple educa-
tional pamphlet (which contained the same information
as the workbook but no graphics or exercises). Of 232
surgeons invited to participate in the study, 76
expressed an interest, but only 57 surgeons ultimately
enrolled patients into the trial (86 patients in the deci-
sion aid arm and 50 in the pamphlet arm). The study
was approved by the Research Ethics Board at the Uni-
versity of Toronto. The main outcome measures were
patient scores on a decisional conflict scale, breast can-
cer knowledge, anxiety, and decisional regret. Data were
obtained from patient questionnaires completed at the
initial consultation, prior to surgery, and 6 months after
enrolment. Research nurses extracted data on pathology
and actual treatment received from the patients’ charts.
No significant differences were observed between the
study arms in knowledge, anxiety or regret, but a non-
significant trend toward lower decisional conflict was
observed in the decision aid group.
The intervention under study was directed at patients,
but administered by their surgeons. Who were the
human research subjects in this study? The patients?
The surgeons?
Methods
This paper seeks to provide a comprehensive definition
of human research subject that is broadly applicable to
CRTs in health research. The method used in this paper
is one that philosophers call ‘reflective equilibrium’ [10].
The process of reflective equilibrium is meant to align a
general rule that guides a person’s reasoning on a parti-
cular issue – in this case, about who is a human
research subject – and the particular judgments he or
she holds on that issue. Using this method, we arrive at
a definition that serves as the basis for reasoning about
who is a human research subject. We then use both the
process and the definition to reflect on new cases and
develop a set of criteria for the identification of human
research subjects.
Following the method of reflective equilibrium, we
first review regulations and the research ethics literature
for criteria that have been developed to identify human
research subjects. Currently available regulatory defini-
tions of research subjects are based on lists of proce-
dures, i.e., an individual may only be classified as a
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research subject if he or she undergoes a procedure
listed in the regulations [11-15]. These regulations con-
stitute prior judgments that regulators have made about
who is a research subject. We will employ these regula-
tory judgments as a foundation on which to construct a
general definition of human research subject: we posit
that a research subject is an individual whose interests
are put at risk as a result of interventions in a research
study. Thus, our definition of human research subject
will capture considered convictions about who is – and
is not – a research subject.
However, the method of reflective equilibrium is not
simply a unidirectional distillation of a general definition
from particular judgments about who is a human
research subject. It requires that as we develop the defi-
nition, if we discover that any particular judgment we
hold conflicts with it, we then have a decision to make
about how to proceed: we may either revise the defini-
tion to accommodate the commitment, or we may
rethink the judgment that is in tension with the defini-
tion developed thus far. Neither the general definition
nor particular commitments are privileged over the
other. This approach allows both reflection on whether
or not current regulatory criteria that identify research
subjects are adequate, as well as reflection on novel
research designs, such as CRTs.
We use the method of reflective equilibrium to speci-
fically develop criteria for the identification of human
research subjects in CRTs. We examine whether the
effects of group-level environmental interventions are,
by themselves, sufficient to make cluster members
human research subjects, and consider the impact of
random assignment on an individual’s status as a
human research subject. We conclude by suggesting
ways that our definition of human research subject may
be applied in a variety of CRT designs and contexts to
identify research subjects who are entitled to regulatory
protections.
Identifying human research subjects
1. Regulatory definitions of human research subject
The definition of research subject is a foundational
question in the ethics of human subjects research.
Nevertheless, many national and international research
ethics guidelines offer no definition of human research
subject [16-20]. One of the few national regulations that
does so is the United States federal regulations on the
“Protection of Human Subjects” [11]. Subpart A of these
regulations is known as the Common Rule and governs
all human subjects research conducted or funded by
departments of the US federal government.
According to the Common Rule, a human research
subject is a:
“living individual about whom an investigator
(whether professional or student) conducting
research obtains
(1) Data through intervention or interaction with the
individual, or
(2) Identifiable private information.
Intervention includes both physical procedures by
which data are gathered (for example, venipuncture)
and manipulations of the subject or the subject’s
environment that are performed for research pur-
poses. Interaction includes communication or inter-
personal contact between investigator and subject.
Private information includes information about
behavior that occurs in a context in which an indivi-
dual can reasonably expect that no observation or
recording is taking place, and information which has
been provided for specific purposes by an individual
and which the individual can reasonably expect will
not be made public (for example, a medical record).
Private information must be individually identifiable
(i.e., the identity of the subject is or may readily be
ascertained by the investigator or associated with the
information) in order for obtaining the information
to constitute research involving human subjects
[11].”
The Australian National Statement on Ethical Con-
duct in Human Research (hereafter, the “National State-
ment”), meanwhile, lists six types of activities that
confer human research subject status on an individual,
including:
“1. taking part in surveys, interviews, or focus
groups;
2. undergoing psychological, physiological or medical
testing or treatment;
3. being observed by researchers;
4. researchers having access to their personal docu-
ments or other materials;
5. the collection and use of their body organs, tissues
or fluids (e.g., skin, blood, urine, saliva, hair, bones,
tumour and other biopsy specimens) or their
exhaled breath;
6. access to their information (in individually identi-
fiable, re-identifiable, or non-identifiable form) as
part of an existing published or unpublished source
or database” [12].
Four of these criteria (1, 2, 3, and 5) describe different
kinds of interventions upon or interactions with sub-
jects, and are therefore reducible to the first item in the
Common Rule criteria ("intervention or interaction with
the individual”). The fourth and sixth items in the
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Australian National Statement criteria refer to the use of
an individual’s information, including both identifiable
private information and information from which perso-
nal identifiers have been removed [12].
Because of their comprehensiveness, and because they
are supported by a great deal of historical documenta-
tion, we will use the Common Rule criteria as our start-
ing point. We will draw on other guidelines, such as the
Australian National Statement, where applicable. We
now ask, do the criteria of the Common Rule share a
core feature? If one can be identified, it may provide the
basis for a comprehensive, generalizable definition of
human research subject.
2. Distinctive features of human research subjects
In attempting to identify a core feature linking the cri-
teria outlined in the Common Rule and other regula-
tions, we are guided by normative work on the
distinction between a patient in clinical practice and a
human subject in clinical research. In the appendices to
the Belmont Report, Robert Levine draws a distinction
between medical practice and clinical research based on
the purpose of each activity [21]. Clinical practice, he
argues, involves a physician acting solely for the purpose
of ameliorating the health of the patient. Research, on
the other hand, is “...a systematic investigation, including
research development, testing and evaluation, designed
to develop or contribute to generalizable knowledge”
[11]. Research may include interventions that offer ben-
efit to research subjects, but these are not essential com-
ponents of an activity whose primary purpose is to
benefit society and generate knowledge. The difference
between the purpose of clinical practice and that of clin-
ical research leads to an important distinction between
the physician-patient and investigator-subject
relationship.
In clinical practice, the physician and patient have a
fiduciary relationship. A fiduciary relationship is a rela-
tionship of structural inequality in which the beneficiary
(in this case, the patient) entrusts the fiduciary (in this
case, the physician) with discretionary power over
important practical interests (in this case, the medical
interests of the patient) [22]. As a result of ceding
power to the fiduciary, the beneficiary is dependent on
the fiduciary and vulnerable to harm. Accordingly, a
number of duties accrue to the fiduciary, including a
duty to act and advise so as to protect the interests at
stake. In the case of the physician-patient relationship,
physicians are obligated to protect and promote the
medical interests of their patients, and to protect their
privacy. Levine points out that in ordinary clinical prac-
tice, patients can be confident that physicians will
endeavor to protect these interests [21].
The relationship between researchers and human
research subjects is somewhat different. Levine and
Rothman note that physician-researchers have conflict-
ing obligations [21,23]. On the one hand, they have obli-
gations to protect the interests of their patient-subjects
[21-23]. On the other hand, physician-researchers also
have obligations to the study, such as ensuring compli-
ance with experimental treatment protocols. These may
conflict with their obligations to protect patient welfare
[21,23]. As Rothman writes, “The bedrock principle of
medical ethics – that the physician acted only to pro-
mote the well-being of the patient – did not hold in the
laboratory...The doctor-patient relationship could no
longer serve as the model for the investigator-subject
relationship.” [23]
Human research subjects are vulnerable because a
physician-investigator’s obligation to protect subjects
may conflict with scientific obligations. As Levine puts
it, the role of a research subject approximates that of a
means to an end [21]. Both the Common Rule and Aus-
tralian National Statement specify ways in which a sub-
ject’s interests may be compromised for scientific
purposes. When a researcher intervenes on a human
research subject, either with an experimental interven-
tion or to collect data, the research subject’s welfare
may be at risk. The same is true when a researcher
interacts with a research subject. By collecting personal
information, the researcher may violate the subject’s
privacy.
3. A definition of human research subject
As noted above, regulatory criteria for human research
subjects may be understood as specifying ways in which
an individual’s interests may be compromised for scien-
tific purposes. Based on this finding, we propose the fol-
lowing definition of a research subject:
A research subject is an individual whose interests
may be compromised as a result of interventions in
a research study.
Interventions (using the term in its broadest sense)
refer to the procedures under investigation in both the
experimental and control arms of the study, as well as
non-therapeutic data collection procedures. Interests
refer to the goods that an individual would ordinarily
seek to protect, including health, welfare, and privacy.
We find historical support for this definition in the
1974 US Department of Health, Education, and Welfare
(DHEW) regulations for human subjects research – the
immediate precursor to the Common Rule [24]. Rather
than define human research subject per se, the DHEW
regulations refer to “subjects at risk”. A subject at risk is:
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“any individual who may be exposed to the possibi-
lity of injury, including physical, psychological, or
social injury as a consequence of participation as a
subject in any research, development, or related
activity which departs from the application of those
established and accepted methods necessary to meet
[the individual’s] needs, or which increases the
ordinary risks of daily life, including the recognized
risks inherent in a chosen occupation or field of
service." [24]
The authors of the DHEW regulations identify effec-
tively the same core feature of human research subject
as we do, namely, “the possibility of injury, including
physical, psychological, or social injury as a consequence
of [research] participation” [24].
4. Evaluating current regulations with the definition
Our novel definition of human research subject may be
used to critically evaluate regulatory criteria for human
research subjects. We use this process to identify our own
set of criteria for the identification of human research sub-
jects. As previously noted, the Australian National State-
ment offers a six-item list of ways in which an individual
may become a human research subject. Four of these cri-
teria (1, 2, 3, and 5) identify ways in which researchers
may intervene upon or interact with subjects. These items
are, therefore, consistent with our definition of human
research subject. The fourth criterion refers to “research-
ers having access to personal documents or materials.”
Such access may compromise subjects’ privacy; this criter-
ion, therefore, merits inclusion [12]. The sixth criterion
defines any individual from whom a researcher obtains
“information (in individually identifiable, re-identifiable, or
non-identifiable form) as part of an existing published or
unpublished database or source” as a human research sub-
ject [12]. While the use of identifiable (and re-identifiable)
information may present a risk to an individual’s privacy,
the use of non-identifiable information presents no such
risk. We conclude that the use of non-identifiable infor-
mation should not be included in criteria identifying
human research subjects.
Are the components of the Common Rule consistent
with our definition of human research subject? The
Common Rule criteria include both interventions on
and interactions with subjects, as well as the use of
identifiable private information. These constitute means
by which research subjects’ interests may be compro-
mised, and, therefore, merit inclusion in criteria specify-
ing human research subjects (see Table 1). The
Common Rule widens the description of interventions
to include both “physical procedures” and “manipula-
tions of the subject or the subject’s environment.” [11]
Given that physical procedures or manipulations of the
subject necessarily involve some degree of risk, and may
compromise the subject’s welfare interests, they merit
inclusion. However, the relevance of “manipulations...of
the subject’s environment” to human research subjects
requires detailed examination.
The importance of environmental manipulation
As specified in the Common Rule, one way in which an
investigator may intervene on human research subjects
is by manipulating their environment. With respect to
healthcare CRTs, Mann and Reyes have interpreted this
to mean that an intervention designed to alter a health-
care professional’s practice pattern entails a manipula-
tion of the environment of all patients whose care may
be affected [7]. According to Mann and Reyes, every
patient of a professional whose care may be influenced
by a study intervention in a CRT meets the regulatory
definition of a human research subject. This claim is
understandable, given that much of the literature on the
ethics of CRTs assumes that all cluster members (in this
case, patients) will be subjects [2,20,25-28]. If correct,
this view has important implications for the conduct of
CRTs. If, in CRTs targeted at health professionals or
health systems in general, all patients are considered
human research subjects, the administrative burdens
associated with protecting patients as human research
subjects may threaten the feasibility of trials. We explore
below whether the indirect effects of a research inter-
vention at the group level (such as an educational inter-
vention administered to health professionals) implies
that all individuals within the group (including the
patients of professionals participating) must be consid-
ered human research subjects.
1. Does environmental manipulation confer the status of
human research subject on individuals?
The CIOMS International Ethical Guidelines for Biome-
dical Research Involving Human Subjects defines
Table 1 The identification of human research subjects: a definition and a set of criteria.
Definition A human research subject is an individual whose interests may be compromised as a result of interventions in a research study.
Criteria A human research subject is:
1. An individual who is directly intervened upon by an investigator;
2. An individual who is deliberately intervened upon via manipulation of the individual’s environment by an investigator;
3. An individual with whom an investigator interacts for the purpose of collecting data; or,
4. An individual about whom an investigator obtains identifiable private information for the purpose of collecting data.
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research as any study that manipulates an individual’s
social or physical environment [17]. These guidelines,
together with the CIOMS International Ethical Guide-
lines for Epidemiological Studies, address issues of
informed consent and harm-benefit analysis in epide-
miologic research [20]. Therefore, without actually
defining research subject, both CIOMS guidelines
appear to acknowledge that individuals who may be
directly affected by public health interventions that
manipulate the environment, such as water fluoridation
or pesticide use, are human research subjects [17,20].
An unduly broad interpretation of environmental
manipulation is, however, untenable. It seems implausi-
ble that everyone whose environment is manipulated in
the context of a research project should be considered a
human research subject. The term environment refers
to “the surroundings or conditions in which a person,
animal, or plant lives or operates” [29]. Using this defi-
nition, “manipulations of the...subject’s environment”
would imply that entire populations might be involved
in a research study. For example, studies in particle phy-
sics at the Large Hadron Collider meet the Common
Rule definition of research, in that they are systematic
investigations designed to develop generalizable knowl-
edge and constitute “manipulations of...the environment”
[11]. Do the citizens of France and Switzerland thus
become human research subjects? If experiments at the
Large Hadron Collider are theoretically capable of pro-
ducing microscopic black holes, does that imply that
everyone on earth is a human research subject [30]?
Clearly, a more restrictive interpretation of environmen-
tal manipulation is required.
It is helpful to consider what the US National Com-
mission for the Protection of Human Subjects of Biome-
dical and Behavioral Research meant when it included
environmental manipulation in its definition of a human
research subject. In a paper prepared for the National
Commission in 1975 (included in the 1979 appendix to
the Belmont Report), Robert Levine defined research as
“...manipulation, observation, or other study of a human
being – or of anything related to that human being that
might subsequently result in manipulation of that
human being – done with the intent of developing new
knowledge and which differs in any way from customary
medical (or other professional) practice” [22]. Specific
reference to manipulation of an individual’s environ-
ment did not appear until the National Commission’s
1978 Report and Recommendations: Institutional Review
Boards which replaced Levine’s definition of “anything
related to that human being that might subsequently
result in manipulation of that human being” with
“manipulations of...the subject’s environment” [31]. This
latter language was subsequently incorporated into the
Common Rule. Exploring the reasons for this change in
regulatory language helps us understand how to inter-
pret environmental manipulation in the context of
human subjects research.
Given the research ethics literature at the time, it
seems likely that the National Commission was seeking
to protect individuals who participated in studies evalu-
ating the psychological effects of various environmental
stimuli. Inclusion of environmental manipulation in the
criteria for human research subjects seemed intended to
cover research that deliberately manipulated subjects
and jeopardized their welfare without physical contact.
Examples of such research include studies examining
the psychological and behavioural effects of habitation
in simulated fallout shelters sponsored by the US Office
of Civil and Defense Mobilization and studies evaluating
the psychological effects of other environmental manip-
ulations, such as sensory deprivation [32-34]. Environ-
mental manipulations in the Civil Defense studies
involved living in a confined space for prolonged periods
of time, crowding, and variations in air quality, tempera-
ture and the availability of potable water. These manipu-
lations of the environment caused human research
subjects physical and psychological discomfort and jeo-
pardized their welfare.
These studies, and the ethical concerns that they high-
light, support a narrow reading of the environmental
manipulation clause. We suggest that environmental
manipulation must be designed to have a direct effect
on individuals if they are to be considered human
research subjects. We believe that this interpretation is
consistent with the intent of the National Commission.
We will therefore expand our criteria specifying human
research subjects to include individuals who are deliber-
ately affected via manipulation of their environment
(see Table 1).
Our conclusion is also consistent with the language
enshrined in the final report of the National Bioethics
Advisory Commission. In its 2001 Report and Recommen-
dations: Ethical and Policy Issues in Research Involving
Human Participants, the Commission agreed that the
term human research subject “connotes the fact that the
individual is ‘subjected’ to an action by the investigator.”
[35] The Commission specifically recommended that
“Research be considered to involve human participants
when individuals 1) are exposed to manipulations, inter-
ventions, observations or other interactions with investiga-
tors or 2) are identifiable through research using biological
materials, medical and or other records, or databases” [35].
2. Do indirect effects of CRT interventions on health
professionals or health systems confer the status of
human research subject on patients?
Mann and Reyes assert that educational or quality
improvement interventions in a CRT designed to change
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physicians’ practice patterns constitute manipulations of
the environment of participating physicians’ patients [7].
As a result, they conclude that all patients of physicians
whose care may be indirectly affected in such trials are
human research subjects. We respectfully disagree.
First, for an individual to be properly considered a
human research subject, the environmental manipula-
tion must be designed to produce a direct effect on that
individual. This is not the case in CRTs that intervene
on health professionals. The interventions under evalua-
tion in these studies are intended to change health pro-
fessionals’ behaviour by increasing their use of evidence-
based strategies to improve care. Patients are not
manipulated by these interventions; they are only indir-
ectly affected by them.
Second, even if a change in professionals’ practice pat-
terns did constitute a deliberate manipulation of their
patients’ environment (a claim that we do not grant),
that manipulation does not jeopardize patients’ interests
or mean that they ought to be considered human
research subjects. Distinguishing between clinical prac-
tice and clinical research may help clarify matters, As
Levine writes:
“If a physician proceeds in [the] interaction with a
patient to bring what [the physician] considers to be
the best available technique and technology to bear
on the problems of that patient with the intent of
doing the most possible good for that patient, this
may be considered the pure practice of medicine. By
contrast, if a physician interacts with an individual
with the intent of developing new knowledge (not
primarily for the benefit of that individual), this
activity may be classified as research” [21].
In a CRT that intervenes on health professionals, the
participating health professionals are research subjects,
not investigators. They are still bound by professional
responsibility to act in their patients’ best interests.
Thus, patient welfare is not put at risk in CRTs that
evaluate interventions aimed at improving practice.
Some studies evaluate patient level effects as an out-
come measure. The fact that a patient level effect may
be measurable is relevant to patients only insofar as
their private health information may be used, or they
may be asked to submit to surveys or additional exami-
nations to evaluate the outcome of the CRT. When this
occurs, the patients of health professionals participating
in an educational or quality improvement CRT ought to
be considered human research subjects.
CRTs evaluating quality improvement initiatives or
system-wide innovations aimed at healthcare organiza-
tions should be treated similarly to CRTs evaluating
educational interventions aimed at providers. Patients
need only be considered research subjects if they are
directly intervened upon, if they interact with investiga-
tors, or if identifiable private information is used.
CRTs evaluating novel modes of healthcare delivery
must be treated differently if the experimental interven-
tion involves a departure from standard care [36]. Such
CRTs are conducted because the efficacy of the mode of
delivery is uncertain. Randomization to clusters is
undertaken for logistical reasons and to avoid treatment
contamination. Novel modes of healthcare delivery are
therefore best thought of as experimental interventions
directed at patients. In such studies, the patients should
be considered research subjects because they are directly
intervened upon.
3. Implications for CRTs in fields other than healthcare
In some CRTs, particularly in public health, the pur-
pose of the experimental intervention is to deliberately
manipulate individuals via their environment. For
example, in the COMMIT study, described above,
multi-modal community interventions (environmental
manipulations) were intended to produce behavioral
change in smokers living in intervention communities
[3,4]. Another CRT evaluating interventions aimed at
individuals via environmental manipulation compared
rates of diarrheal illness in communities randomly
assigned to water treatment with flocculant disinfec-
tant or a control [37]. In these studies, the purpose of
the environmental manipulation is to intervene on
individual community members. The residents of com-
munities in these studies are therefore human research
subjects and are entitled to regulatory protections.
However, this does not mean that informed consent is
required. Rather, many of these studies would meet
criteria for a waiver of informed consent that are laid
out in various national and international research
ethics guidelines [11,17,18,20]. These guidelines gener-
ally require that the research not be feasible if consent
were required, and that the interventions in the study
pose only minimal risk to subjects – conditions that
are often met by CRTs in public health. (When
informed consent must be obtained in CRTs is the
subject of another paper in this series).
CRTs in education are roughly analogous to CRTs in
healthcare and the teacher-student relationship has
many of the characteristics of a fiduciary relationship
[21]. If a CRT is used to evaluate the effect of a continu-
ing education intervention for teachers, the indirect
effect on students does not require treating them as
human research subjects. However, CRTs of experimen-
tal curricular programs may be analogous to CRTs eval-
uating novel methods of health service delivery, and
may require treating students as human research
subjects.
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What is the importance of random intervention
assignment?
The ethical implications of random assignment to study
interventions in CRTs are unclear. In CRTs, random
group assignment often takes place before subjects are
enrolled [2,25,28]. In CRTs of large cluster level public
health interventions, clusters may be randomly assigned
to interventions that some cluster members never
receive (e.g., smoking cessation messages are not neces-
sarily received by all community members). As the lit-
erature to date has broadly assumed that all cluster
members are human research subjects, this has led to
the conjecture that the act of random assignment may
in itself be sufficient to confer the status of human
research subject on cluster members [28]. In rando-
mized controlled trials (RCTs), assignment of individuals
to the intervention or control arm is determined by a
mechanism beyond the control of the individual; it is
not determined by the physician-patient dyad. Random
assignment has thus been viewed as a research interven-
tion [38]. The corollary of this is that randomization of
individuals or groups may confer the status of human
research subject upon those randomized.
We argue that random assignment does not confer the
status of human research subject. Whether or not it is
random, intervention assignment is beyond the control
of the individual or group. For this reason, the use of ran-
dom intervention assignment is immaterial to the deter-
mination of whether an individual is a research subject. If
some non-random method of intervention assignment
were used in place of random assignment, the threats to
subjects’ liberty and welfare interests would be
unchanged. A human research subject’s interests are jeo-
pardized by participating in research–whether interven-
tion assignment is random or otherwise. Random
assignment of clusters ought not be considered a criter-
ion for the identification of human research subjects. The
fact that, in many CRTs, group assignment is determined
before subject enrolment should be acknowledged in
consent discussions with individuals who are identified as
human research subjects.
Implications for cluster randomized trials
Using a novel definition of human research subject, we
have set out four criteria for their identification (see
Table 1). Here we explore the implications of each of
these criteria for CRTs in health research.
Criterion 1. An individual who is directly intervened upon
by an investigator for research purposes
Individuals ought to be considered human research sub-
jects if, in the context of a research study, they are the
recipients of a study intervention (active or control) or
if they undergo an intervention to collect data, such as
venipuncture.
If an intervention is targeted at individuals but ran-
dom assignment takes place at the cluster level (typically
to avoid treatment contamination or for logistical rea-
sons) then the individuals receiving the intervention
should be considered human research subjects. In
healthcare, this includes CRTs evaluating therapeutic or
health promotion modalities aimed at individual
patients, as well as CRTs evaluating new modes of
health service delivery. An example of the former is a
CRT evaluating the effect of individualized exercise pre-
scriptions for patients randomized by physician practice
[39]. An example of the latter is a CRT evaluating the
effectiveness of asthma management using specialist
nurses [36]. In these studies, the individual patients
themselves are being intervened upon and should there-
fore be considered human research subjects.
In many healthcare CRTs, the intervention under study
is not administered to patients, but rather to healthcare
professionals, even though outcomes are evaluated using
patient data. It may be asked whether health professionals
who receive an educational intervention in a CRT are
human research subjects or collaborators. Collaborators
are individuals who contribute to the design of or partici-
pate in the conduct of a research study. They are not reci-
pients of study interventions. In knowledge translation
CRTs, the health professionals are receiving an experimen-
tal educational or quality improvement intervention.
When they are directly intervened upon in this way, health
professionals are human research subjects [7,8,40].
Some healthcare CRTs evaluate complex interventions
that may include a combination of health professional
education, novel modes of health service delivery, and
patient level interventions [41]. In these cases, determin-
ing whether healthcare providers or patients or both
ought to be considered human research subjects
requires that research ethics committees trace the
impact of each study intervention and data collection
procedure. When study interventions are directed at
health professionals, they are human research subjects.
Patients ought to be considered research subjects if:
patient level interventions (either therapeutic interven-
tions or data collection procedures) or novel modes of
health service delivery are used; researchers interact
with them; or, the study uses their identifiable private
information to evaluate outcomes.
Criterion 2. An individual who is deliberately intervened
upon via manipulation of the individual’s environment by
an investigator for research purposes
Individuals who are intervened upon through manipula-
tion of their environment ought to be considered
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human research subjects. This includes individuals
affected by public health interventions in CRTs, whether
the unit of randomization is a municipality, a neigh-
bourhood, a family, or some other group. Because these
individuals are human research subjects, they are
entitled to regulatory protections, including assessment
by a research ethics committee of study benefits and
harms. These studies may meet regulatory criteria for a
waiver of informed consent if interventions pose mini-
mal risk and the study is not feasible if individual
informed consent must be obtained.
We concluded above that the indirect effects of a
study intervention on an individual are not sufficient to
warrant considering that person a human research sub-
ject. In healthcare CRTs, patients may be indirectly
affected by educational or quality improvement inter-
ventions that are directed at healthcare professionals or
institutions. The physicians under study continue to
have an obligation to act in their patients’ best interests,
and have no competing obligations to the study itself.
Thus, the physician-patient fiduciary relationship is pre-
served. If there are no patient level interventions, the
researcher has no interaction with individual patients,
and there is no use of identifiable private information
for research purposes, patients are not human research
subjects.
Criterion 3. An individual with whom an investigator
interacts for the purpose of collecting data
An individual from whom an investigator, in the con-
text of a research study, obtains data through interac-
tion should be considered a human research subject.
Interaction includes communication or interpersonal
contact between investigator and subject, for example,
interviews, focus groups, or questionnaires. Data col-
lection through interaction entails that respondents are
entitled to protections as human research subjects
[11,12].
Criterion 4. An individual from whom an investigator
obtains identifiable private information for the purpose
of collecting data
Obtaining identifiable private information about people
within a cluster means they ought to be considered
human research subjects, and that they are entitled to
protection. Conversely, there is no risk to an individual’s
privacy if the researchers are only collecting anonymized
or aggregate group-level information [42]. Individuals
whose data have been anonymized before transfer to the
investigators, or whose administrative or health-related
information is used to generate aggregate measures for a
cluster are not human research subjects unless they are
intervened upon in some other way.
Practical applications for ethics review of CRTs
We will now apply our novel definition and criteria for
the identification of human research subjects to the
example CRTs.
Example 1: The COMMIT Trial
The multi-modal community intervention constitutes an
environmental manipulation directed at all community
residents. Therefore, people in the intervention commu-
nities ought to be considered human research subjects.
Data were collected using surveys of cross sectional sam-
ples of the community and prospective cohorts of smokers,
and survey respondents (whether from intervention or con-
trol communities) are human research subjects. Residents
of control communities were not intervened upon, did not
interact with investigators (unless they completed surveys),
and did not contribute identifiable private information.
Therefore, residents of control communities who were not
survey respondents are not human research subjects.
Example 2: A CRT of bed net distribution to reduce
malaria prevalence
The distribution of bed nets constitutes a direct inter-
vention on individuals. Therefore, all residents of the
intervention communities who received a bed net ought
to be considered human research subjects. Individuals
contributing blood samples, whether from intervention
or control communities, were directly intervened upon
and are therefore human research subjects. Members of
control communities were not intervened upon (unless
they contributed blood samples), did not interact with
investigators, and did not contribute identifiable perso-
nal information. Therefore, members of control commu-
nities who did not contribute blood samples are not
human research subjects.
Example 3: A CRT comparing interventions to improve
primary care prescribing
The physicians in this study were recipients of an
experimental intervention in that they received one of
two candidate quality improvement interventions, and
ought to be considered human research subjects. The
patients were indirectly affected by the interventions
directed at the physicians, but they received no interven-
tion from study personnel, had no interaction with study
personnel, and contributed no identifiable private infor-
mation. Therefore, the patients of physicians participat-
ing in this study are not human research subjects.
Example 4: A CRT comparing modes of educating
patients prior to breast cancer surgery
In this study, the patients were recipients of an experimen-
tal intervention in that they received one of two candidate
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modes of education about their surgical options. They
responded to questionnaires to generate outcome data;
they also contributed identifiable medical information. As
a result, the patients ought to be considered human
research subjects. The surgeons merely delivered the study
interventions to the patients and were not themselves the
recipients of interventions; they did not otherwise interact
with researchers to provide data, nor did they provide
identifiable private information. Thus, the surgeons are
not human research subjects.
Conclusions
We have defined a human research subject as an indivi-
dual whose interests may be compromised as a result of
interventions in a research study, and have specified
four criteria for the identification of human research
subjects (see Table 1). Human research subjects are:
those intervened upon by researchers, either directly or
by deliberate manipulation of their environment; those
who interact with researchers to provide data; or those
who provide identifiable private information.
In articulating a novel definition of a human research
subject and a set of criteria for their identification, this
paper represents an essential first step in addressing
additional questions on how to protect human research
subjects in CRTs. Subsequent papers in this series will
use this definition of human research subject and
address informed consent, clinical equipoise, the analysis
of harms and benefits, subject selection, the protection
of vulnerable subjects, and the role and authority of
gatekeepers in CRTs in health research.
Note
We have created a Wiki webpage to facilitate an open
discussion about the ideas expressed in this and other
papers published in the series on ethical challenges in
CRTs. Please enter your thoughts and comments at
http://crtethics.wikispaces.com.
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